Clinical trials: Diagnosis, Dual (Psychiatry)
Dual Diagnosis
Matching, Outcomes and Costs in Substance Abuse/Psychiatric Treatment
This project�s goal is to improve the quality of care and reduce treatment costs for veterans with substance abuse and psychiatric problems.
- Trial name
- NCT00012727
- Testing
- Matching Symptom Severity to Service Intensity
- Where
- 6 sites in United States
- Volunteers
- 236 people
- Sponsor
- US Department of Veterans Affairs
Paralysis, Hyperkalemic Periodic, Hypokalemic Periodic Paralysis
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders
OBJECTIVES: I. Assess the efficacy of dichlorphenamide in the treatment of episodic weakness attacks in patients with hyperkalemic periodic paralysis, paramyotonia congenita with periodic paralysis, and hypokalemic periodic…
- Conditions
- Paralysis, Hyperkalemic Periodic, Hypokalemic Periodic Paralysis, Paramyotonia Congenita
- Trial name
- NCT00004802
- Testing
- dichlorphenamide
- Volunteers
- 64 people
- Sponsor
- National Center for Research Resources (NCRR)
Diagnosis, Dual (Psychiatry)
Dual Diagnosis Inpatients: Telephone Monitoring RCT to Improve Outcomes
This research program will improve the care and treatment outcomes of dually diagnosed veterans who receive inpatient psychiatry care, and decrease their use of VA inpatient mental health services.
- Trial name
- NCT01135420
- Testing
- Telephone Monitoring (TM) with Motivational Interviewing, Usual care
- Where
- 2 sites in United States
- Volunteers
- 406 people
- Sponsor
- VA Office of Research and Development
Schizophrenia
Effects of Buspirone Combined With Clozapine
This study aimed to evaluate the enhancing effects of different doses of buspirone on psychiatric symptoms and cognitive function in patients with schizophrenia.
- Trial name
- NCT06906224
- Testing
- Low-dose group (buspirone tablets, clozapine), High-dose group (buspirone tablets, clozapine)
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Chuanfu Song
Multiple Sclerosis
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Copolymer 1 for Relapsing-Remitting Multiple Sclerosis
OBJECTIVES: I. Compare tolerance to and therapeutic impact of copolymer 1, a mixture of synthetic polypeptides, with placebo in patients with relapsing-remitting multiple sclerosis.
- Trial name
- NCT00004814
- Testing
- copolymer 1
- Volunteers
- 250 people
- Sponsor
- National Center for Research Resources (NCRR)
Mental Disorder, Intellectual Disability
Mental Health Care Provision for Adults With Intellectual Disability and a Mental Disorder
Quality of mental health services provision for adults with intellectual disability and comorbid mental disorder is considered inadequate and therefore in need of further improvement.
- Trial name
- MEMENTA (NCT01695395)
- Where
- 3 sites in Germany
- Volunteers
- 371 people
- Sponsor
- Technische Universität Dresden
ADHD, Attention Deficit Hyperactivity Disorder
A Double-Blind Comparison of Naltrexone and Placebo in Adults With Attention Deficit Hyperactivity Disorder
The primary aim of this study is to assess whether naltrexone as a monotherapy is effective in treating ADHD in adults. Medications that increase dopamine are often effective treatments for ADHD.
- Trial name
- NCT01721330
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Massachusetts General Hospital
Mental Health Issue, Substance Use Disorders
Co-Active Therapeutic Theatre (Co-ATT) for Dual-Diagnosis Patients
Drama Therapy involves of the use of theatrical techniques (such as script development, acting exercises, improvisation, etc.) to help treat patients' mental illness and improve their functioning and overall sense of wellbeing.
- Trial name
- Co-ATT (NCT06187701)
- Testing
- Co-Active Therapeutic Theatre (Co-ATT)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Boston Medical Center
SCHIZOPHRENIA 1 (Disorder), Substance Abuse
Comparison of the Italian and U.S. Forensic Models for Dual-diagnosis Offenders: a 3-year Longitudinal Study
This study aims to compare the Italian and U.S. forensic models in the treatment of offenders with dual diagnosis through a three-year longitudinal design.
- Trial name
- NCT07585656
- Volunteers
- 600 people
- Sponsor
- University of Bari
Dyskinesia, Medication-induced
Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia
An 8-week study to examine safety and efficacy of levetiracetam in patients with neuroleptic-induced tardive dyskinesia
- Trial name
- NCT00175955
- Testing
- Levetiracetam
- Where
- 7 sites in Belgium, Bulgaria
- Volunteers
- 70 people
- Sponsor
- UCB Pharma
Spinal Cord Injury
Methylprednisolone Given by 24-Hour or 48-Hour Infusion Versus Tirilazad for Acute Spinal Cord Injury
OBJECTIVES: I. Compare the efficacy and safety of 24- versus 48-hour infusion of methylprednisolone (MePRDL) versus tirilazad for patients with acute spinal cord injury. II.
- Trial name
- NCT00004759
- Testing
- methylprednisolone, tirilazad
- Volunteers
- 497 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy
OBJECTIVES: I. Compare and evaluate the response to treatment with intravenous human immune globulin (IVIG) or placebo in previously untreated patients with chronic inflammatory demyelinating polyneuropathy.
- Trial name
- NCT00004286
- Testing
- immune globulin
- Volunteers
- 120 people
- Sponsor
- National Center for Research Resources (NCRR)
Generalized Anxiety Disorder
Kava for the Treatment of Generalised Anxiety Disorder: A Double-Blind Randomised Placebo-Controlled Trial
The use of Kava in Generalised Anxiety Disorder: an 18-week double-blind, randomised, placebo-controlled study.
- Trial name
- KGAD (NCT02219880)
- Testing
- Kava (240mg of kavalactones per day)
- Where
- 2 sites in Australia
- Volunteers
- 178 people
- Sponsor
- University of Melbourne
Acute Disseminated Encephalomyelitis, Devic's Syndrome
Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone
OBJECTIVES: I. Evaluate the effectiveness of plasma exchange in the treatment of acute severe attacks of inflammatory demyelinating disease in patients who have failed intravenous steroid therapy.
- Conditions
- Acute Disseminated Encephalomyelitis, Devic's Syndrome, Marburg's Variant of Multiple Sclerosis, Balo's Concentric Sclerosis
- Trial name
- NCT00004645
- Testing
- Plasma exchange
- Volunteers
- 22 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Alcoholism, Diagnosis, Dual (Psychiatry)
12-step Facilitation for the Dually Diagnosed
This is a randomized trial testing the efficacy of a modified 12-step facilitation therapy for individuals with serious mental illness and alcohol use disorders, compared to usual treatment.
- Trial name
- TSFDD (NCT00583440)
- Testing
- 12-step facilitation, Treatment as usual
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- University of New Mexico
Patients, Anxiety Disorders
LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders
Background: Lysergic acid diethylamide (LSD) was extensively investigated in humans in the 1950s and 1960s. Particularly, LSD attenuated anxiety in patients with cancer.
- Trial name
- LSD-assist (NCT03153579)
- Testing
- LSD
- Where
- 2 sites in Switzerland
- Volunteers
- 46 people
- Sponsor
- University Hospital, Basel, Switzerland
Cortical Excitability, Psychiatric Disorder
Effects of L-theanine on Motor Cortex Excitability in Healthy Subjects: A Paired-Pulse TMS Study
Major depressive disorder (MDD) is a serious mental illness and the leading cause of disability worldwide. New pharmacotherapeutic agents with complementary neurobiological mechanism and better side effect profile are of great…
- Trial name
- NCT04749745
- Testing
- L-theanine
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Butler Hospital
Social Anxiety Disorder, Anxiety Disorders
A Study Of A New Medicine (GW679769) For The Treatment Of Social Anxiety Disorder
The purpose of this study is to test the safety and efficacy of GW679769 and paroxetine in subjects with Social Anxiety Disorder
- Trial name
- NCT00273039
- Testing
- paroxetine
- Where
- 27 sites in United States, Argentina and 4 more
- Volunteers
- 242 people
- Sponsor
- GlaxoSmithKline
Tourette Syndrome
Phase II Double Blind Placebo Controlled Trial of Risperidone in Tourette Syndrome
OBJECTIVES: I. Conduct a randomized, double blind, placebo controlled, parallel study of the atypical neuroleptic risperidone (RIS) in the treatment of children and adults with moderate to severe Tourette Syndrome. II.
- Trial name
- NCT00004393
- Testing
- risperidone
- Volunteers
- 50 people
- Sponsor
- National Center for Research Resources (NCRR)
Autoimmune Diseases, Mental Disorders Diagnosed in Childhood
Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg)
Recent research studies of early onset-obsessive compulsive disorder (OCD) and Tourette's syndrome have questioned whether autoimmunity could play a role in the development of these conditions.
- Conditions
- Autoimmune Diseases, Mental Disorders Diagnosed in Childhood, Schizophrenia
- Trial name
- NCT00001768
- Testing
- Intravenous immunoglobulin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Mental Health (NIMH)